Clinical trials: Depressed
Treatment Resistant Depression
Multiple Ascending Dose Phase 1 Study of ALA-3000
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression…
- Trial name
- NCT06965569
- Testing
- ALA-3000, escitalopram, sertraline, duloxetine or venlafaxine XR
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alar Pharmaceuticals Inc.
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Bipolar Depression
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult…
- Trial name
- NCT00938301
- Testing
- PF-04455242
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Antidepressant Treatment of AIDS Related Depression.
To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.
- Trial name
- NCT00000390
- Testing
- Imipramine hydrochloride
- Where
- United States
- Sponsor
- GEIGY Pharmaceuticals
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression
Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl
This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S.
- Trial name
- NCT00788944
- Testing
- blood draw
- Where
- 52 sites in United States
- Volunteers
- 971 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pregnancy Related, Mental Health Issue
MamaConecta: Digital Tool for Maternal Mental Health
The goal of this randomized controlled trial is to validate a digital health tool, Dana app, that enhances well-being and supports mental health monitoring for women during the perinatal period.
- Conditions
- Pregnancy Related, Mental Health Issue, Postpartum Depression, Postpartum Anxiety
- Trial name
- DDT (NCT06442774)
- Testing
- Mobile application, Monitoring via wearable
- Where
- 3 sites in Spain
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- A Thousand Colibris, S.L
Post-traumatic Stress Disorder, Depression
Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD
Post-Traumatic Stress Disorder (PTSD) is a mental disorder that may develop in people who have been exposed to a traumatic event, including actual or threatened death, serious injury, or sexual violence.
- Trial name
- SUMMIT-90 (NCT06141876)
- Testing
- APEX-002-A02
- Volunteers
- 160 people
- Sponsor
- Apex Labs Ltd.
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Depressive Disorder, Major
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
- Trial name
- NCT03352453
- Testing
- Rapastinel
- Where
- 17 sites in United States
- Volunteers
- 138 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder.
- Trial name
- NEST-MDD (NCT01370733)
- Testing
- NEST-1 (NeoSync EEG Synchronized TMS)
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Treatment Resistant Depression
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
- Trial name
- NCT05711940
- Testing
- Psilocybin
- Where
- 116 sites in United States, Canada and 10 more
- Volunteers
- 572 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder, Treatment Resistant Depression
An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug.
- Trial name
- TARGET (NCT04971291)
- Testing
- AXS-05, Bupropion SR
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive Disorder
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of…
- Trial name
- NCT00250653
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- Sanofi
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram